AI Engines For more Details: Perplexity Kagi Labs You
Cough Suppression: Dropropizine acts on the cough reflex center in the brain, helping to reduce the frequency and intensity of coughing. It is used to provide relief from both dry, non-productive coughs and coughs associated with excessive mucus production (productive coughs).
Respiratory Conditions: Dropropizine is commonly prescribed for cough relief in respiratory conditions such as the common cold, flu (influenza), bronchitis, sinusitis, and other upper respiratory tract infections. It helps to soothe irritated airways and suppress the urge to cough.
Throat Irritation: Dropropizine may be used to alleviate coughing associated with throat irritation caused by postnasal drip, environmental irritants, or smoking.
Allergic Cough: It can be used to relieve coughing triggered by allergies or allergic reactions, such as hay fever (allergic rhinitis) or allergic asthma.
Chronic Bronchitis: Dropropizine may be prescribed as part of the treatment regimen for chronic bronchitis, a long-term inflammation of the airways characterized by persistent coughing.
Acute Pharyngitis: In cases of acute pharyngitis (sore throat), dropropizine can help reduce coughing and throat irritation, providing temporary relief from symptoms.
Preoperative and Postoperative Cough: Dropropizine may be used before or after surgical procedures to suppress coughing, particularly in patients undergoing procedures that may irritate the airways or throat.
Productive Cough: While dropropizine is primarily a cough suppressant, it may also help to loosen and facilitate the removal of mucus from the respiratory tract, especially in cases of productive cough.
Pediatric Use: Dropropizine may be prescribed for children above a certain age for the relief of cough associated with respiratory infections. However, it is important to use pediatric formulations and follow pediatric dosing guidelines.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| Taxonomy | Rank | Effect | Citations | Notation |
|---|---|---|---|---|
| unclassified Robinsoniella | no rank | Decreases | ⚗️ Source Study | |
| unclassified Fusobacterium | no rank | Decreases | ⚗️ Source Study | |
| unclassified Negativicoccus | no rank | Decreases | ⚗️ Source Study | |
| Eggerthellales | order | Decreases | ⚗️ Source Study | |
| Anaerofustis stercorihominis | species | Decreases | ⚗️ Source Study | |
| Asaccharospora irregularis | species | Decreases | ⚗️ Source Study | |
| Negativicoccus sp. S5-A15 | species | Decreases | ⚗️ Source Study | |
| Paraprevotella clara | species | Decreases | ⚗️ Source Study | |
| Slackia sp. NATTS | species | Decreases | ⚗️ Source Study | |
| Pseudoflavonifractor capillosus | species | Decreases | ⚗️ Source Study | |
| [Collinsella] massiliensis | species | Decreases | ⚗️ Source Study | |
| Parvibacter caecicola | species | Decreases | ⚗️ Source Study | |
| Coriobacterineae | suborder | Decreases | ⚗️ Source Study | |
| Chlamydiae/Verrucomicrobia group | superphylum | Decreases | ⚗️ Source Study |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Chronic Fatigue Syndrome | 0.1 | 0.1 | |
| Depression | 0.3 | 0.3 | |
| ME/CFS without IBS | 0.1 | 0.1 | |
| Mood Disorders | 0.3 | 0.3 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.